Total Payments
$28,952
2024 Payments
$5,195
Companies
12
Transactions
66
Medicare Patients
1,951
Medicare Billing
$223,844
Payment Breakdown by Category
Research$23,655 (81.7%)
Travel$2,719 (9.4%)
Consulting$1,500 (5.2%)
Food & Beverage$1,037 (3.6%)
Education$41.38 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,655 | 14 | 81.7% |
| Travel and Lodging | $2,719 | 7 | 9.4% |
| Consulting Fee | $1,500 | 1 | 5.2% |
| Food and Beverage | $1,037 | 43 | 3.6% |
| Education | $41.38 | 1 | 0.1% |
Payments by Type
Research
$23,655
14 transactions
General
$5,298
52 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $23,510 | 11 | $0 (2024) |
| EISAI INC. | $2,998 | 10 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,675 | 6 | $0 (2017) |
| Biogen, Inc. | $307.82 | 9 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $224.88 | 16 | $0 (2021) |
| Astellas Pharma US Inc | $63.24 | 3 | $0 (2017) |
| PFIZER INC. | $58.66 | 4 | $0 (2019) |
| Allergan Inc. | $32.42 | 2 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $29.53 | 2 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.88 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,195 | 1 | Eli Lilly and Company ($5,195) |
| 2023 | $355.00 | 1 | Eli Lilly and Company ($355.00) |
| 2022 | $4,517 | 14 | Eli Lilly and Company ($2,966) |
| 2021 | $12,574 | 9 | Eli Lilly and Company ($10,948) |
| 2020 | $61.12 | 4 | Janssen Pharmaceuticals, Inc ($61.12) |
| 2019 | $90.28 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21.88) |
| 2018 | $3,554 | 11 | Eli Lilly and Company ($3,309) |
| 2017 | $2,606 | 20 | Novartis Pharmaceuticals Corporation ($1,675) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,195.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $355.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 12/05/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 12/05/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 12/05/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $48.75 | General |
| 12/05/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| 12/05/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $12.50 | General |
| 12/04/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $654.96 | General |
| 12/04/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $366.76 | General |
| 12/04/2022 | EISAI INC. | — | Travel and Lodging | Cash or cash equivalent | $165.00 | General |
| 12/04/2022 | EISAI INC. | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 07/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $414.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 05/10/2022 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Neurology | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $2,054.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $498.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 04/05/2022 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Neurology | ||||||
| 12/07/2021 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: NEUROLOGY | ||||||
| 11/28/2021 | Eli Lilly and Company | — | — | In-kind items and services | $339.60 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 11/02/2021 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| 10/11/2021 | Biogen, Inc. | — | Education | In-kind items and services | $41.38 | General |
| 09/21/2021 | Biogen, Inc. | ADUHELM (Biological) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: NEUROLOGY | ||||||
| 05/18/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/04/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,344.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 03/06/2021 | Eisai Inc. | None (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: None | ||||||
| 02/17/2021 | Eli Lilly and Company | — | — | In-kind items and services | $3,263.97 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $11,106 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $5,609 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | Eli Lilly and Company | $3,889 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $2,394 | 2 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $157.80 | 1 |
| 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Biogen, Inc. | $144.33 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 370 | 668 | $153,910 | $46,167 |
| 2022 | 13 | 446 | 707 | $167,635 | $50,399 |
| 2021 | 14 | 541 | 1,034 | $212,409 | $67,012 |
| 2020 | 16 | 594 | 947 | $182,729 | $60,266 |
Total Patients
1,951
Total Services
3,356
Medicare Billing
$223,844
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 47 | 252 | $38,136 | $10,050 | 26.4% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 54 | 59 | $26,702 | $8,644 | 32.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 55 | 57 | $22,242 | $7,667 | 34.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 93 | $16,820 | $5,842 | 34.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 39 | $11,616 | $3,910 | 33.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 52 | 56 | $13,106 | $3,579 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 29 | $6,769 | $2,675 | 39.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 18 | $5,843 | $1,722 | 29.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 31 | 37 | $8,674 | $1,390 | 16.0% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 15 | 28 | $4,002 | $687.56 | 17.2% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Office | 2022 | 84 | 87 | $37,752 | $11,527 | 30.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 56 | 62 | $23,332 | $9,804 | 42.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 53 | 221 | $32,148 | $6,905 | 21.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 42 | 73 | $12,776 | $4,194 | 32.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 37 | $8,304 | $3,373 | 40.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 29 | 30 | $8,568 | $3,296 | 38.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 42 | 46 | $10,338 | $2,690 | 26.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 44 | 51 | $11,436 | $2,110 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 15 | $4,464 | $2,090 | 46.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 19 | $5,956 | $1,576 | 26.5% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $4,254 | $1,177 | 27.7% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Office | 2022 | 25 | 42 | $5,766 | $988.28 | 17.1% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 11 | 13 | $2,541 | $669.08 | 26.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 75 | 78 | $28,068 | $12,830 | 45.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 59 | 367 | $51,000 | $11,564 | 22.7% |
About Dr. John Stoukides, MD
Dr. John Stoukides, MD is a Geriatric Medicine healthcare provider based in East Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639176357.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Stoukides, MD has received a total of $28,952 in payments from pharmaceutical and medical device companies, with $5,195 received in 2024. These payments were reported across 66 transactions from 12 companies. The most common payment nature is "" ($23,655).
As a Medicare-enrolled provider, Stoukides has provided services to 1,951 Medicare beneficiaries, totaling 3,356 services with total Medicare billing of $223,844. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Location East Providence, RI
- Active Since 07/07/2005
- Last Updated 01/15/2019
- Taxonomy Code 207QG0300X
- Entity Type Individual
- NPI Number 1639176357
Products in Payments
- None (Drug) $1,500
- CNP520 (Drug) $953.30
- XARELTO (Drug) $224.88
- ADUHELM (Biological) $97.12
- ELIQUIS (Drug) $75.73
- Myrbetriq (Drug) $63.24
- NAMZARIC (Drug) $32.42
- STIOLTO RESPIMAT (Drug) $21.88
- AUSTEDO (Drug) $15.16
- COPAXONE (Drug) $14.37
- SILENOR (Drug) $13.37
- ENTRESTO (Drug) $8.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.